tetano
Editor, Senior Moderator
Emerg Microbes Infect
. 2025 Jun 6:2511132.
doi: 10.1080/22221751.2025.2511132. Online ahead of print. Computationally designed haemagglutinin with nanocage plug-and-display elicits pan-H5 influenza vaccine responses
Chloe Qingzhou Huang[SUP] 1 [/SUP], Rory A Hills[SUP] 2 3 [/SUP], George W Carnell[SUP] 1 4 [/SUP], Sneha Vishwanath[SUP] 1 [/SUP], Ernest T Aguinam[SUP] 1 [/SUP], Andrew C Y Chan[SUP] 1 [/SUP], Phil Palmer[SUP] 1 [/SUP], Laura O'Reilly[SUP] 1 [/SUP], Paul Tonks[SUP] 1 [/SUP], Nigel Temperton[SUP] 5 [/SUP], Simon D W Frost[SUP] 6 7 8 9 [/SUP], Laurence S Tiley[SUP] 6 [/SUP], Mark R Howarth[SUP] 2 [/SUP], Jonathan L Heeney[SUP] 1 9 [/SUP]
Affiliations
The increasing spread of highly pathogenic avian influenza (HPAI) A/H5 viruses poses a pandemic threat. Circulating clade 2.3.4.4b viruses have demonstrated rapid transcontinental dissemination, extensive reassortment, epizootic spread and potential sustained mammal-to-mammal transmission, signifying a heightened risk of becoming a human pathogen of high consequence. A broadly protective, future-proof vaccine against multiple clades of H5 influenza is urgently needed for pandemic preparedness. Here, we combine two novel vaccine technologies to generate a Digitally Immune Optimised and Selected H5 antigen (DIOSvax-H5[SUB]inter[/SUB]) displayed multivalently on the mi3 nanocage using the SpyTag003/SpyCatcher003 conjugation system. Mice immunised with DIOSvax-H5[SUB]inter[/SUB] Homotypic Nanocages at low doses demonstrate potent, cross-clade neutralising antibody and T cell responses against diverse H5 strains. DIOSvax-H5[SUB]inter[/SUB] Homotypic Nanocages provide a scalable vaccine candidate with the potential for pan-H5 protection against drifted or newly emergent H5 strains. This World Health Organization preferred characteristic is essential for prospective strategic stockpiling in the pre-pandemic phase.Trial registration: ClinicalTrials.gov identifier: NCT06145178..
Keywords: Avian Influenza; Computational Biology; Nanoparticles; Pandemic Preparedness; Protein Engineering; Universal Influenza Vaccine; Virus-Like Particles.
. 2025 Jun 6:2511132.
doi: 10.1080/22221751.2025.2511132. Online ahead of print. Computationally designed haemagglutinin with nanocage plug-and-display elicits pan-H5 influenza vaccine responses
Chloe Qingzhou Huang[SUP] 1 [/SUP], Rory A Hills[SUP] 2 3 [/SUP], George W Carnell[SUP] 1 4 [/SUP], Sneha Vishwanath[SUP] 1 [/SUP], Ernest T Aguinam[SUP] 1 [/SUP], Andrew C Y Chan[SUP] 1 [/SUP], Phil Palmer[SUP] 1 [/SUP], Laura O'Reilly[SUP] 1 [/SUP], Paul Tonks[SUP] 1 [/SUP], Nigel Temperton[SUP] 5 [/SUP], Simon D W Frost[SUP] 6 7 8 9 [/SUP], Laurence S Tiley[SUP] 6 [/SUP], Mark R Howarth[SUP] 2 [/SUP], Jonathan L Heeney[SUP] 1 9 [/SUP]
Affiliations
- PMID: 40476519
- DOI: 10.1080/22221751.2025.2511132
The increasing spread of highly pathogenic avian influenza (HPAI) A/H5 viruses poses a pandemic threat. Circulating clade 2.3.4.4b viruses have demonstrated rapid transcontinental dissemination, extensive reassortment, epizootic spread and potential sustained mammal-to-mammal transmission, signifying a heightened risk of becoming a human pathogen of high consequence. A broadly protective, future-proof vaccine against multiple clades of H5 influenza is urgently needed for pandemic preparedness. Here, we combine two novel vaccine technologies to generate a Digitally Immune Optimised and Selected H5 antigen (DIOSvax-H5[SUB]inter[/SUB]) displayed multivalently on the mi3 nanocage using the SpyTag003/SpyCatcher003 conjugation system. Mice immunised with DIOSvax-H5[SUB]inter[/SUB] Homotypic Nanocages at low doses demonstrate potent, cross-clade neutralising antibody and T cell responses against diverse H5 strains. DIOSvax-H5[SUB]inter[/SUB] Homotypic Nanocages provide a scalable vaccine candidate with the potential for pan-H5 protection against drifted or newly emergent H5 strains. This World Health Organization preferred characteristic is essential for prospective strategic stockpiling in the pre-pandemic phase.Trial registration: ClinicalTrials.gov identifier: NCT06145178..
Keywords: Avian Influenza; Computational Biology; Nanoparticles; Pandemic Preparedness; Protein Engineering; Universal Influenza Vaccine; Virus-Like Particles.